Review of medical abortion using mifepristone in combination with a prostaglandin analogue.

Induced abortion is still a major health problem in the world and the most frequently performed intervention in obstetrics and gynecology with an estimated total of 46 million worldwide each year. Medical abortion with mifepristone and prostaglandin was first introduced in 1988 and is now approved in 31 countries. This combination of drugs has recently been included in the List of Essential Medicines by the World Health Organisation. The present review summarizes the development, physiology and the development of the currently used regimens.

[1]  L. Ivy,et al.  A study of co-treatment of nonsteroidal anti-inflammatory drugs (NSAIDs) with misoprostol for cervical priming before suction termination of first trimester pregnancy , 2003 .

[2]  M. Bygdeman,et al.  Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. , 1985, Contraception.

[3]  S. Suhonen,et al.  One- and 2-day mifepristone-misoprostol intervals are both effective in medical termination of second-trimester pregnancy. , 2004, Reproductive biomedicine online.

[4]  Ching Yin Grace Wong,et al.  A study of co-treatment of nonsteroidal anti-inflammatory drugs (NSAIDs) with misoprostol for cervical priming before suction termination of first trimester pregnancy. , 2003, Contraception.

[5]  A death associated with mifepristone/ sulprostone , 1991, The Lancet.

[6]  P. Darney,et al.  Misoprostol and pregnancy. , 2001, The New England journal of medicine.

[7]  K. Gemzell‐Danielsson,et al.  Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. , 2005, European journal of obstetrics, gynecology, and reproductive biology.

[8]  P. Stewart,et al.  A comparison of medical and surgical termination of pregnancy: choice, emotional impact and satisfaction with care , 1998, British journal of obstetrics and gynaecology.

[9]  K. Matsumoto,et al.  RU486, a progestin antagonist, binds to progesterone receptors in a human endometrial cancer cell line and reverses the growth inhibition by progestins. , 1988, Journal of steroid biochemistry.

[10]  C. Ellertson,et al.  Mifepristone-misoprostol medical abortion: home administration of misoprostol in Guadeloupe. , 1999, Contraception.

[11]  P. Ho,et al.  Blood loss in termination of early pregnancy by vacuum aspiration and by combination of mifepristone and gemeprost. , 1993, Contraception.

[12]  H. Chen,et al.  Stabilization and sustained-release effect of misoprostol with methacrylate copolymer. , 2000, International journal of pharmaceutics.

[13]  E. Baulieu,et al.  Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. , 1985, The Journal of clinical endocrinology and metabolism.

[14]  M. Creinin,et al.  Effect of nonsteroidal anti-inflammatory drugs on the action of misoprostol in a regimen for early abortion. , 1997, Contraception.

[15]  V. Odlind,et al.  The antiprogestational agent RU 486 as an abortifacient in early human pregnancy: a comparison of three dose regimens. , 1988, Contraception.

[16]  Sunita Sharma,et al.  Oral, Rectal, and Vaginal Pharmacokinetics of Misoprostol , 2004, Obstetrics and gynecology.

[17]  I. Cameron,et al.  A controlled release form of 16,16-dimethyl-trans-Δ2-PGE1methyl ester for early abortion , 1986 .

[18]  K. Holmgren.  Women's evaluation of three early abortion methods , 1992, Acta obstetricia et gynecologica Scandinavica.

[19]  M. Bygdeman,et al.  The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin , 1988, British journal of obstetrics and gynaecology.

[20]  E. Baulieu,et al.  ACTIVITE CONTRAGESTIVE DE L'ASSOCIATION AU RU486 D'UNE PROSTAGLANDINE ACTIVE PAR VOIE ORALE , 1991 .

[21]  P. Madelenat,et al.  Efficacité et acceptabilité de l'interruption volontaire de grossesse par méthode médicamenteuse pratiquée sans hospitalisation dans le cadre d'un réseau ville–hôpital : étude prospective sur 433 patientes , 2005 .

[22]  C. Fiala,et al.  Rh‐prophylaxis in early abortion , 2003, Acta obstetricia et gynecologica Scandinavica.

[23]  S. Fielding,et al.  Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. , 2001, Contraception.

[24]  Roger P. Smith.  The Dynamics of Nonsteroidal Anti‐Inflarnmatory Therapy for Primary Dysmenorrhea , 1987, Obstetrics and gynecology.

[25]  D. Urquhart,et al.  The use of mifepristone prior to prostaglandin-induced mid-trimester abortion. , 1990, Human reproduction.

[26]  M. Bygdeman,et al.  Abortion in early pregnancy by vaginal administration of 16,16-dimethyl-PGE2 in comparison with vacuum aspiration , 1977 .

[27]  G. Piaggio,et al.  WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: Efficacy , 2003, BJOG : an international journal of obstetrics and gynaecology.

[28]  G. Acharya,et al.  Role of routine ultrasonography in monitoring the outcome of medical abortion in a clinical setting , 2004, Acta obstetricia et gynecologica Scandinavica.

[29]  S. Fielding,et al.  Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. , 2002, Contraception.

[30]  C. Fiala,et al.  The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13-22 weeks gestation. , 2005, Human reproduction.

[31]  I. Sivin,et al.  Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol. Results of a large multicenter trial in the United States. Mifepristone Clinical Trials Group. , 1998, Archives of family medicine.

[32]  E. Baulieu,et al.  Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol [corrected]. , 1995, International journal of fertility and menopausal studies.

[33]  E. Fliers,et al.  A prostaglandin analogue as a probable cause of myocardial infarction in a young woman. , 1991, BMJ.

[34]  S. Fielding,et al.  Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. , 2000, Contraception.

[35]  L. Lewin.  Die Fruchtabtreibung durch Gifte und Andere Mittel : ein Handbuch für Ärzte und Juristen , 2022 .

[36]  H. vonHertzen.  Research on regimens for early medical abortion. , 2000 .

[37]  K. Gemzell‐Danielsson,et al.  Termination of second trimester pregnancy with mifepristone and gemeprost , 2000 .

[38]  M. Nichols,et al.  The roles of clinical assessment, human chorionic gonadotropin assays, and ultrasonography in medical abortion practice. , 2000, American journal of obstetrics and gynecology.

[39]  Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. , 1993 .

[40]  A. Templeton,et al.  Nonsurgical mid‐trimester termination of pregnancy: a review of 500 consecutive cases , 1999, British journal of obstetrics and gynaecology.

[41]  Richard D. Alexander,et al.  A Comparative Review , 1968 .

[42]  N. Wiqvist,et al.  Prostaglandins, indomethacin and dysmenorrhea. , 1976, Prostaglandins.

[43]  D. Mishell,et al.  Early pregnancy termination with vaginal misoprostol combined with loperamide and acetaminophen prophylaxis. , 2001, Contraception.

[44]  S. Fielding,et al.  Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. , 2000, JAMA.

[45]  E. Baulieu,et al.  Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol , 1993, The New England journal of medicine.

[46]  S. Fielding,et al.  Original research article Comparison of misoprostol plasma concentrations following buccal and sublingual administration , 2005 .

[47]  R. Sitruk-Ware,et al.  Fetal malformation and failed medical termination of pregnancy , 1998, The Lancet.

[48]  I. Sivin,et al.  Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol. Results of a large multicenter trial in the United States. Mifepristone Clinical Trials Group. , 1998, Archives of family medicine.

[49]  G. Penney,et al.  An effective regimen for early medical abortion: a report of 2000 consecutive cases. , 1998, Human reproduction.

[50]  R. Sitruk-Ware,et al.  Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. , 2003, Contraception.

[51]  A. Templeton,et al.  Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. , 1995 .

[52]  P. Wong,et al.  Comparison between oral and vaginal administration of misoprostol on uterine contractility. , 1999, Obstetrics and gynecology.

[53]  N. Chabbert-Buffet,et al.  Management of patients receiving long-term treatment with mifepristone. , 2005, Fertility and sterility.

[54]  W. Keane,et al.  Disposition of Misoprostol and its Active Metabolite in Patients With Normal and Impaired Renal Function , 1995, Journal of clinical pharmacology.

[55]  Angela Y. Chen,et al.  A Randomized Comparison of Misoprostol 6 to 8 Hours Versus 24 Hours After Mifepristone for Abortion , 2004, Obstetrics and gynecology.

[56]  O. Heikinheimo,et al.  The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancy. , 2002, Human reproduction.

[57]  H. Croxatto,et al.  Metabolism and serum binding of RU 486 in women after various single doses. , 1987, Human reproduction.

[58]  J. Trussell,et al.  Estimating the efficacy of medical abortion. , 1999, Contraception.

[59]  M. Bygdeman,et al.  Effects of misoprostol on uterine contractility following different routes of administration. , 2004, Human reproduction.

[60]  H. Croxatto,et al.  Pharmacokinetics and metabolism of RU 486. , 1987, Journal of steroid biochemistry.

[61]  A. Spira,et al.  Analysis of 369 abortions conducted by mifepristone (RU486) associated with sulprostone in a French family planning center , 1994, Fertility and sterility.

[62]  K. Kontula,et al.  Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. , 1987, Journal of steroid biochemistry.

[63]  A. Haspels.  Interruption of early pregnancy by an anti-progestational compound, RU 486. , 1985, European journal of obstetrics, gynecology, and reproductive biology.

[64]  M. Bygdeman,et al.  Antiprogestational steroids: a new dimension in human fertility regulation. , 1989, Oxford reviews of reproductive biology.

[65]  S. Fielding,et al.  Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. , 2005, Contraception.

[66]  L. Helström,et al.  Sublingual compared with oral misoprostol for cervical dilatation prior to vacuum aspiration: a randomized comparison. , 2004, Contraception.

[67]  M. Vessey,et al.  Misoprostol and illegal abortion in Rio de Janeiro, Brazil , 1993, The Lancet.

[68]  Participants are listed on page.  Lowering the doses of mifepristone and gemeprost for early abortion: a randomised controlled trial , 2001 .

[69]  I. Mackenzie,et al.  The physiological and clinical effects of progesterone inhibition with mifepristone (RU 486) in the second trimester , 1990, British journal of obstetrics and gynaecology.

[70]  C. Gottlieb,et al.  Uterine Contractility and Interaction between Prostaglandins and Antiprogestins Clinical Implications , 1991, Annals of the New York Academy of Sciences.

[71]  K. Barnhart,et al.  Is Rh immune globulin needed in early first-trimester abortion? A review. , 2003, American journal of obstetrics and gynecology.

[72]  W. Abdullah.  Asia-Oceania J Obstet Gynaecol , 1993 .

[73]  M. Cox.  Misoprostol and the debate over off-label drug use , 2005, Journal of Family Planning and Reproductive Health Care.

[74]  D. Baird,et al.  Pretreatment with mifepristone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortion , 1990, British journal of obstetrics and gynaecology.

[75]  G. Penney,et al.  The acceptability of home medical abortion to women in UK settings , 2005, BJOG : an international journal of obstetrics and gynaecology.

[76]  V. Odlind,et al.  Early pregnancy termination with antiprogestins: a comparative clinical study of RU 486 given in two dose regimens and Epostane. , 1987, Fertility and sterility.

[77]  G. Piaggio,et al.  WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. , 2004, BJOG : an international journal of obstetrics and gynaecology.

[78]  N. Benowitz,et al.  Absorption Kinetics of Misoprostol With Oral or Vaginal Administration , 1997, Obstetrics and gynecology.

[79]  C. Fiala,et al.  Acceptability of home-use of misoprostol in medical abortion. , 2004, Contraception.

[80]  D. Philibert,et al.  Biochemical Profile of RU 486 , 1985 .

[81]  A. Templeton,et al.  Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and their effect on blood pressure , 1994, British journal of obstetrics and gynaecology.

[82]  J. Salmon,et al.  Pharmacokinetics of RU 486. , 1985 .

[83]  D. Baird,et al.  A pilot study of the effect of methotrexate or combined oral contraceptive on bleeding patterns after induction of abortion with mifepristone and a prostaglandin pessary. , 1998, Contraception.

[84]  B. Winikoff,et al.  Misoprostol alone--a new method of medical abortion? , 2000, Journal of the American Medical Women's Association.

[85]  P. Iqbal,et al.  Early pregnancy termination: a comparison between vacuum aspiration and medical abortion using prostaglandin (16,16 dimethyl‐trans‐Δ2‐PGE1 methyl ester) or the antiprogestogen RU 486 , 1988, British Journal of Obstetrics and Gynaecology.

[86]  J. Schwartz,et al.  Mifepristone followed on the same day by vaginal misoprostol for early abortion. , 2002, Contraception.

[87]  P. Ho,et al.  Vaginal Misoprostol Compared With Oral Misoprostol in Termination of Second‐Trimester Pregnancy , 1997, Obstetrics and gynecology.

[88]  A. Templeton,et al.  Mifepristone versus vaginally administered misoprostol for cervical priming before first-trimester termination of pregnancy: a randomized, controlled study. , 2000, American journal of obstetrics and gynecology.

[89]  E. Baulieu,et al.  Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue: Study in 16, 369 women , 1992, Acta obstetricia et gynecologica Scandinavica.

[90]  Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. World Health Organization. , 1991, Fertility and sterility.

[91]  E. Wiebe.  Pain control in medical abortion , 2001, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[92]  D. Baird,et al.  Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation. , 2001, Human reproduction.

[93]  E. Baulieu,et al.  Termination of early pregnancy by the progesterone antagonist RU 486 (Mifepristone). , 1986, The New England journal of medicine.

[94]  Uk Multicentre Trial.  The efficacy and tolerance of mifepristone and prostaglandin in first trimester termination of pregnancy , 1990 .

[95]  U. Turpeinen,et al.  Pharmacokinetics of the antiprogesterone RU 486: no correlation to clinical performance of RU 486. , 1990, Acta endocrinologica.

[96]  A. Templeton,et al.  The abortifacient effect of misoprostol in the second trimester. A randomized comparison with gemeprost in patients pre-treated with mifepristone (RU486). , 1993, Human reproduction.

[97]  R. Henshaw,et al.  Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. , 1993, BMJ.

[98]  V. Odlind.  Induced abortion--a global health problem. , 1997, Acta obstetricia et gynecologica Scandinavica. Supplement.

[99]  M. Choolani,et al.  Blood Loss in Termination of Early Pregnancy with Mifepristone and Gemeprost , 1995, The Australian & New Zealand journal of obstetrics & gynaecology.

[100]  S. Miller,et al.  Control of myometrial contractility: role and regulation of gap junctions. , 1988, Oxford reviews of reproductive biology.

[101]  B. Winikoff,et al.  Misoprostol for Women's Health: A Review , 2002, Obstetrics and gynecology.

[102]  S. Naji,et al.  Psychological responses following medical abortion (using mifepristone and gemeprost) and surgical vacuum aspiration a patient‐centered, partially randomised prospective study , 1994, Acta obstetricia et gynecologica Scandinavica.

[103]  P. Ho,et al.  A prospective randomized study on the measured blood loss in medical termination of early pregnancy by three different misoprostol regimens after pretreatment with mifepristone. , 2002, Human reproduction.

[104]  C. Bardin,et al.  Clinical pharmacology of RU 486--an antiprogestin and antiglucocorticoid. , 1993, Contraception.

[105]  Bruce J. West,et al.  Chaos and fractals in human physiology. , 1990, Scientific American.

[106]  P. Franks,et al.  Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. , 1997, The Journal of family practice.

[107]  L. L. Stevenson,et al.  Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. , 1991, Journal of neurosurgery.

[108]  C. Bardin,et al.  Early pregnancy termination with mifepristone and misoprostol in the United States. , 1998, The New England journal of medicine.

[109]  M. Creinin,et al.  A pilot study of mifepristone and misoprostol administered at the same time for abortion up to 49 days gestation. , 2005, Contraception.

[110]  C. Ellertson,et al.  Blood loss with mifepristone–misoprostol abortion: measures from a trial in China, Cuba and India , 1998, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[111]  R. Basu,et al.  Mifepristone and misoprostol for medical termination of pregnancy: the effectiveness of a flexible regimen , 2003, Journal of Family Planning and Reproductive Health Care.

[112]  P. Chambon,et al.  A single amino acid that determines the sensitivity of progesterone receptors to RU486. , 1992, Science.

[113]  B. Winikoff.  Acceptability of medical abortion in early pregnancy. , 1995, Family planning perspectives.

[114]  B. Winikoff,et al.  A Fatal Case of Clostridium sordellii Septic Shock Syndrome Associated With Medical Abortion , 2004, Obstetrics and gynecology.

[115]  G. Teutsch,et al.  [The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy]. , 1982, Comptes rendus des seances de l'Academie des sciences. Serie III, Sciences de la vie.

[116]  D. Baird,et al.  Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone , 1991, The Lancet.

[117]  A. Csapo.  "Prostaglandin impact" for menstrual induction. , 1974, Population reports. Series G, Prostaglandins.

[118]  O. Heikinheimo,et al.  The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. , 2003, Contraception.

[119]  P. Ho,et al.  The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol: a randomized placebo controlled trial. , 2002, Human reproduction.

[120]  G. Teutsch,et al.  Analogues of RU 486 for the Mapping of the Progestin Receptor: Synthetic and Structural Aspects , 1985 .

[121]  M. Bygdeman,et al.  Options for early therapeutic abortion: a comparative review. , 2002, Drugs.

[122]  A. Templeton,et al.  Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases , 2002, BJOG : an international journal of obstetrics and gynaecology.

[123]  P. Ho,et al.  Pilot study on the use of sublingual misoprostol for medical abortion. , 2001, Contraception.

[124]  I. Shah,et al.  Unsafe abortion: Global and regional estimates of the incidence of unsafe abortion and associated mortality in 2008. Sixth edition. , 2004 .

[125]  A. Csapo,et al.  Effects of luteectomy and progesterone replacement therapy in early pregnant patients. , 1973, American journal of obstetrics and gynecology.

[126]  P. Ho,et al.  Termination of pregnancy with reduced doses of mifepristone , 1994, BMJ.

[127]  A. Templeton,et al.  A randomized comparison of medical abortion and surgical vacuum aspiration at 10-13 weeks gestation. , 2002, Human reproduction.

[128]  M. Bygdeman,et al.  Cervical softening with mifepristone (RU 486) after pretreatment with naproxen. A double-blind randomized study. , 1992, Contraception.

[129]  M. Bygdeman,et al.  Regulation of non-pregnant human uterine contractility. Effect of antihormones. , 1990, Contraception.

[130]  P. Ho,et al.  Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. , 2000, Human reproduction.

[131]  S. Naji,et al.  Medical abortion or vacuum aspiration? Two year follow up of a patient preference trial , 1997, British journal of obstetrics and gynaecology.

[132]  D. Baird,et al.  Induction of abortion with mifepristone and misoprostol in early pregnancy , 1992 .

[133]  L. Kovács,et al.  Termination of very early pregnancy by RU 486--an antiprogestational compound. , 1984, Contraception.

[134]  E. Aubény.  A two-stage increase in the dose of misoprostol improves the efficacy of medical abortion with mifepristone and prostaglandins , 2001, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[135]  H. von Hertzen.  Research on regimens for early medical abortion. , 2000, Journal of the American Medical Women's Association.

[136]  J. Schwartz,et al.  Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial , 2001, BJOG : an international journal of obstetrics and gynaecology.

[137]  M. Creinin,et al.  A pilot study of mifepristone and misoprostol administered at the same time for abortion in women with gestation from 50 to 63 days. , 2005, Contraception.

[138]  Z. Ye,et al.  Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women. , 1993, Contraception.

[139]  C. McKinley,et al.  Pregnancy: The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol , 1993 .

[140]  J. Grinsted,et al.  Interruption of early pregnancy with mifepristone in combination with gemeprost , 1999, Acta obstetricia et gynecologica Scandinavica.

[141]  E. Baulieu,et al.  Treatment of endometriosis with the antiprogesterone mifepristone (RU486) , 1996, Fertility and sterility.

[142]  A. Ben‐Chetrit,et al.  Mifepristone does not induce cervical softening in non-pregnant women. , 2004, Human reproduction.

[143]  V. Poukens,et al.  Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. , 2005, The New England journal of medicine.

[144]  Urquhart,et al.  The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study--final results. , 1997, Contraception.

[145]  P. Safar,et al.  Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. , 2003, European journal of obstetrics, gynecology, and reproductive biology.

[146]  B. Winikoff,et al.  Infection after medical abortion: a review of the literature. , 2004, Contraception.

[147]  E. Baulieu.  Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor , 1989 .

[148]  S. Fielding,et al.  Perspectives on Sexual and Reproductive Health Having an Abortion Using Mifepristone and Home Misoprostol: a Qualitative Analysis of Women's Experiences , 2022 .

[149]  S. Yen,et al.  Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. , 1995, Fertility and sterility.

[150]  D. Baird,et al.  Uterine activity and decidual prostaglandin production in women in early pregnancy in response to mifepristone with or without indomethacin in vivo. , 1991, Human reproduction.

[151]  P. Ho,et al.  A randomized double-blind placebo-controlled study to assess the effect of oral contraceptive pills on the outcome of medical abortion with mifepristone and misoprostol. , 1999, Human reproduction.

[152]  C. Harper,et al.  Could American women use mifepristone-misoprostol pills safely with less medical supervision? , 2002, Contraception.

[153]  C. Fiala,et al.  Effects of slow release misoprostol on uterine contractility in early pregnancy. , 2005, Human reproduction.

[154]  Sheldon J. Segal,et al.  The Antiprogestin Steroid RU 486 and Human Fertility Control , 2012, Reproductive Biology.

[155]  D. Baird,et al.  Changes in the concentration of alpha‐fetoprotein and placental hormones following two methods of medical abortion in early pregnancy , 1993, British journal of obstetrics and gynaecology.

[156]  P. Tappenden,et al.  A review of the clinical effectiveness of routine antenatal anti‐D prophylaxis for rhesus‐negative women who are pregnant , 2004, BJOG : an international journal of obstetrics and gynaecology.

[157]  R. Caldeyro-barcia,et al.  OXYTOCIN AND CONTRACTILITY OF THE PREGNANT HUMAN UTERUS * , 1959, Annals of the New York Academy of Sciences.

[158]  P. Ho,et al.  Pharmacokinetics of different routes of administration of misoprostol. , 2002, Human reproduction.

[159]  A. Abdulla,et al.  The clinical spectrum of Clostridium sordellii bacteraemia: two case reports and a review of the literature , 2000, Journal of clinical pathology.

[160]  Geneva.  Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial , 2000, BJOG : an international journal of obstetrics and gynaecology.

[161]  A. Templeton,et al.  A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation. , 2003, Contraception.

[162]  D. Clark.  Oxford reviews of reproductive biology , 1985 .

[163]  B. Winikoff,et al.  Multicenter Trial of a Simplified Mifepristone Medical Abortion Regimen , 2005, Obstetrics and gynecology.

[164]  A. Templeton,et al.  Medical abortion at 9-13 weeks' gestation: a review of 1076 consecutive cases. , 2005, Contraception.

[165]  D. Urquhart,et al.  Psychiatric morbidity and acceptibility following medical and surgical methods of induced abortion , 1992, British journal of obstetrics and gynaecology.

[166]  M. Bygdeman,et al.  Medical termination of early pregnancy: the Swedish experience. , 2000, Journal of the American Medical Women's Association.

[167]  D. Grimes.  MEDICAL ABORTION IN EARLY PREGNANCY: A REVIEW OF THE EVIDENCE , 1997, Obstetrics and gynecology.

[168]  K. Gemzell‐Danielsson,et al.  Termination of second trimester pregnancy with mifepristone and gemeprost. The clinical experience of 197 consecutive cases. , 2000, Acta obstetricia et gynecologica Scandinavica.

[169]  A. Sorhaindo,et al.  In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol. , 2000, Journal of the American Medical Women's Association.

[170]  J. Olsen,et al.  Short‐term complications after surgically induced abortions: a register‐based study of 56 117 abortions , 2002, Acta obstetricia et gynecologica Scandinavica.

[171]  F. Granath,et al.  Pharmacokinetics of a novel oral slow-release form of misoprostol. , 2005, Human reproduction.

[172]  J. Legarth,et al.  Mifepristone or vacuum aspiration in termination of early pregnancy. , 1991, European journal of obstetrics, gynecology, and reproductive biology.

[173]  S. Wu.  Medical abortion in China. , 2000, Journal of the American Medical Women's Association.

[174]  P. Ho,et al.  Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy. , 2000, Human reproduction.

[175]  E. Eisenhauer,et al.  Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  M. Bygdeman,et al.  Effect of antiprogestin, hCG and a prostaglandin analogue on human uterine contractility. , 1993, Contraception.

[177]  I. Cameron,et al.  Therapeutic abortion in early pregnancy with antiprogestogen RU486 alone or in combination with prostaglandin analogue (gemeprost). , 1986, Contraception.

[178]  S. Fielding,et al.  Monitoring serum chorionic gonadotropin levels after mifepristone abortion. , 2001, Contraception.